Key Highlights

  • Ionis Pharmaceuticals received FDA approval for Zanvastro to treat Alexander disease in children and adults.
  • The approval was backed by Phase 1-3 results showing stabilized gait speed in patients aged five and up.
  • Younger patients showed improved gross motor function, with a favorable safety profile overall.
  • The drug earned a Rare Pediatric Disease Priority Review Voucher, with a U.S. launch expected within weeks.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) received FDA approval for Zanvastro to treat Alexander disease in both children and adults.

What Happened

The decision was backed by Phase 1-3 results demonstrating stabilized gait speed for patients aged five and up, alongside improved gross motor function in younger populations. The drug maintained a favorable safety profile and earned a Rare Pediatric Disease Priority Review Voucher.

Market Reaction

The disclosed information does not include stock price or trading data for Ionis Pharmaceuticals following the FDA approval.

Outlook

A domestic commercial launch of Zanvastro is slated for the next few weeks, representing the next major milestone for the newly approved therapy.